Centivo has launched a new health plan solution, aimed at lowering costs for employees; trial results show dead bacteria may be effective in treating IBS; continuous glucose monitoring systems are now being used in hospitalized patients with diabetes and coronavirus disease 2019 (COVID-19).
Today, Centivo launched a self-funded health plan solution, available to employers in New York City and Orlando and Jacksonville Florida. The new plan options for employees include low-cost, primary care—based models. Advanced analytics that create cost-effective networks with health systems and independent practice partners will help employees navigate the health system and lead patients to the right specialists. Centivo will partner with Mount Sinai Health System and ProHealth in New York and with Orlando Health in Florida. The goal is to bring down healthcare costs by incentivizing providers to focus on high-value care.Results from a clinical trial published in The Lancet show that probiotics containing dead bacteria may be effective in relieving irritable bowel syndrome (IBS). In the trial, 221 participants received dead Bifidobacteria, which has been shown to be effective in live forms yet can cause severe adverse effects. Around one-third of patients who received the treatment reported reduced abdominal pain compared with only 19% who reported the same outcome in the placebo group; however, over 90% of participants in the treatment group also reported that the adverse effects were tolerable.Continuous glucose monitoring systems produced by Abbott and Dexcom are now being used in hospitalized patients with diabetes and coronavirus disease 2019 (COVID-19) to provide remote monitoring of glucose levels. The companies hope the technology will help limit health workers’ exposure to patients with COVID-19, while providing optimal care for patients with diabetes. The CDC notes diabetes is one of the underlying health conditions that, when poorly managed, can lead to more severe outcomes in patients with COVID-19. Currently, more that 50% of individuals with diabetes who also have COVID-19 are hospitalized, the CDC reports.
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Key Issues Influencing 2022 Employer Health Care Strategy and Plan Design
August 31st 2021On this episode of Managed Care Cast, we speak with Ellen Kelsay, president and CEO of the Business Group on Health, on the findings from her organization's 2022 Large Employers’ Health Care Strategy and Plan Design Survey.
Listen